iCAD (ICAD) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Nov. 07, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	iCAD, Inc.
Entity Central Index Key	0000749660
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Trading Symbol	ICAD
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	NH
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		25,446,407
Entity Tax Identification Number	02-0377419
Entity File Number	001-09341
Entity Incorporation, State or Country Code	DE
Entity Address, City or Town	Nashua
Entity Address, Address Line One	98 Spit Brook Road, Suite 100
Entity Address, Postal Zip Code	03062
City Area Code	603
Local Phone Number	882-5200

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 24,590	$ 34,282
Trade accounts receivable, net of allowance for doubtful accounts of $778 and $268 as of September 30, 2022 and December 31, 2021, respectively	8,472	8,891
Inventory, net	5,630	4,171
Prepaid expenses and other current assets	3,787	2,962
Total current assets	42,479	50,306
Property and equipment, net of accumulated depreciation of $7,275 and 7,106 as of September 30, 2022 and December 31, 2021, respectively	986	882
Operating lease assets	2,945	1,059
Other assets	67	899
Intangible assets, net of accumulated amortization of $8,820 and $8,724 as of September 30, 2022 and December 31, 2021, respectively	535	683
Goodwill	8,362	8,362
Total assets	55,374	62,191
Current liabilities:
Accounts payable	2,423	2,779
Accrued and other expenses	5,544	5,642
Lease payable—current portion	508	889
Deferred revenue—current portion	6,126	5,652
Total current liabilities	14,601	14,962
Lease payable, net of current	2,480	266
Deferred revenue, long-term portion	631	441
Deferred tax	4	5
Total liabilities	17,716	15,674
Commitments and Contingencies (Note 13)
Stockholders' equity:
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued
Common stock, $0.01 par value: authorized 60,000,000 shares; issued 25,428,935 as of September 30, 2022 and 25,326,086 as of December 31, 2021.	254	253
Additional paid-in capital	302,560	300,859
Accumulated deficit	(263,741)	(253,180)
Treasury stock at cost, 185,831 shares as of both September 30, 2022 and December 31, 2021	(1,415)	(1,415)
Total stockholders' equity	37,658	46,517
Total liabilities and stockholders' equity	$ 55,374	$ 62,191

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 778	$ 268
Property and equipment, accumulated depreciation and amortization	7,275	7,106
Intangible assets, accumulated amortization	$ 8,820	$ 8,724
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	25,428,935	25,326,086
Common stock, shares outstanding	25,243,104	25,140,255
Treasury stock, shares	185,831	185,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 6,356	$ 9,361	$ 21,454	$ 25,830
Cost of revenue:
Total cost of revenue	1,983	2,649	6,278	7,291
Gross profit	4,373	6,712	15,176	18,539
Operating expenses:
Engineering and product development	2,137	2,285	6,780	6,745
Marketing and sales	3,473	3,886	10,473	10,739
General and administrative	2,667	2,658	8,341	7,461
Amortization and depreciation	56	64	180	178
Total operating expenses	8,333	8,893	25,774	25,123
Loss from operations	(3,960)	(2,181)	(10,598)	(6,584)
Other income/ (expense):
Interest expense	(7)	0	(7)	(141)
Interest income	71	21	89	53
Other loss, net	(2)	(16)	(45)	(41)
Loss on extinguishment of debt		0	0	(386)
Other expense, net	62	5	37	(515)
Loss before provision for income taxes	(3,898)	(2,176)	(10,561)	(7,099)
Provision for tax expense	0	0	0	0
Net loss and comprehensive loss	$ (3,898)	$ (2,176)	$ (10,561)	$ (7,099)
Net loss per share:
Basic	$ (0.15)	$ (0.09)	$ (0.42)	$ (0.29)
Diluted	$ (0.15)	$ (0.09)	$ (0.42)	$ (0.29)
Weighted average number of shares used in computing loss per share:
Basic	25,204	25,053	25,183	24,662
Diluted	25,204	25,053	25,183	24,662
Product [Member]
Revenue:
Total revenue	$ 3,207	$ 6,320	$ 12,242	$ 16,429
Cost of revenue:
Total cost of revenue	1,416	1,807	4,530	4,592
Service [Member]
Revenue:
Total revenue	3,149	3,041	9,212	9,401
Cost of revenue:
Total cost of revenue	494	763	1,524	2,462
Amortization and depreciation [Member]
Cost of revenue:
Total cost of revenue	$ 73	$ 79	$ 224	$ 237

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2020	$ 30,525	$ 236	$ 273,639	$ (241,935)	$ (1,415)
Beginning Balance, shares at Dec. 31, 2020		23,694,406
Issuance of common stock related to vesting of restricted stock	(59)	$ 1	(60)
Issuance of common stock related to vesting of restricted stock, shares		43,831
Issuance of common stock, net	23,229	$ 14	23,215
Issuance of common stock, net, shares		1,393,738
Issuance of common stock pursuant to stock option plans	933	$ 2	931
Issuance of common stock pursuant to stock option plans, shares		138,450
Issuance of common stock pursuant Employee Stock Purchase Plan	190		190
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		17,412
Stock-based compensation	2,102		2,102
Net loss	(7,099)			(7,099)
Ending Balance at Sep. 30, 2021	49,821	$ 253	300,017	(249,034)	(1,415)
Ending Balance, shares at Sep. 30, 2021		25,287,837
Beginning Balance at Jun. 30, 2021	51,027	$ 251	299,049	(246,858)	(1,415)
Beginning Balance, shares at Jun. 30, 2021		25,213,302
Issuance of common stock related to vesting of restricted stock	(59)	$ 1	(60)
Issuance of common stock related to vesting of restricted stock, shares		14,665
Issuance of common stock, net	297	$ 1	296
Issuance of common stock, net, shares		54,702
Issuance of common stock pursuant Employee Stock Purchase Plan	76		76
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		5,168
Stock-based compensation	656		656
Net loss	(2,176)			(2,176)
Ending Balance at Sep. 30, 2021	49,821	$ 253	300,017	(249,034)	(1,415)
Ending Balance, shares at Sep. 30, 2021		25,287,837
Beginning Balance at Dec. 31, 2021	46,517	$ 253	300,859	(253,180)	(1,415)
Beginning Balance, shares at Dec. 31, 2021		25,326,086
Issuance of common stock related to vesting of restricted stock	0	$ 0	0
Issuance of common stock related to vesting of restricted stock, shares		875
Issuance of common stock pursuant to stock option plans	$ 206	$ 1	205
Issuance of common stock pursuant to stock option plans, shares	73,500	73,833
Issuance of common stock pursuant Employee Stock Purchase Plan	$ 127	$ 0	127
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		28,141
Stock-based compensation	1,369		1,369
Net loss	(10,561)			(10,561)
Ending Balance at Sep. 30, 2022	37,658	$ 254	302,560	(263,741)	(1,415)
Ending Balance, shares at Sep. 30, 2022		25,428,935
Beginning Balance at Jun. 30, 2022	40,990	$ 254	301,994	(259,843)	(1,415)
Beginning Balance, shares at Jun. 30, 2022		25,373,858
Issuance of common stock pursuant to stock option plans	127	$ 0	127
Issuance of common stock pursuant to stock option plans, shares		45,000
Issuance of common stock pursuant Employee Stock Purchase Plan	34	$ 0	34
Issuance of common stock pursuant Employee Stock Purchase Plan, shares		10,077
Stock-based compensation	405		405
Net loss	(3,898)			(3,898)
Ending Balance at Sep. 30, 2022	$ 37,658	$ 254	$ 302,560	$ (263,741)	$ (1,415)
Ending Balance, shares at Sep. 30, 2022		25,428,935

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flow from operating activities:
Net loss	$ (10,561)	$ (7,099)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization	158	176
Depreciation	246	242
Non-cash lease expense	549	581
Bad debt provision	510	(25)
Stock-based compensation	1,369	2,102
Amortization of debt discount and debt costs	0	17
Loss on extinguishment of debt	0	386
Changes in operating assets and liabilities:
Accounts receivable	(91)	(1,827)
Inventory	(1,459)	(146)
Prepaid and other assets	7	493
Accounts payable	(351)	(217)
Accrued and other expenses	(98)	(2,095)
Lease liabilities	(602)	(514)
Deferred revenue	663	65
Total adjustments	901	(762)
Net cash used for operating activities	(9,660)	(7,861)
Cash flow from investing activities:
Additions to patents, technology and other	(10)	(24)
Additions to property and equipment	(355)	(426)
Net cash used for investing activities	(365)	(450)
Cash flow from financing activities:
Proceeds from option exercises pursuant to stock option plans	206	933
Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plans	127	190
Proceeds from issuance of common stock, net	0	23,229
Issuance of stock upon conversion of debentures	0	(7,363)
Taxes paid related to restricted stock program	0	(59)
Net cash provided by financing activities	333	16,930
(Decrease) increase in cash and cash equivalents	(9,692)	8,619
Cash and cash equivalents, beginning of period	34,282	27,186
Cash and cash equivalents, end of period	24,590	35,805
Supplemental disclosure of cash flow information:
Interest paid	7	92
Amendment to right-of-use assets obtained in exchange for operating lease liabilities	$ 2,434	$ 0

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 1 – Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at September 30, 2022, the results of operations of the Company for the three and nine months ended September 30, 2022 and 2021, cash flows of the Company for the nine months ended September 30, 2022 and 2021, and stockholders’ equity for the Company for the three and nine months ended September 30, 2022 and 2021. Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K Principles of Consolidation and Business Segments The condensed consolidated financial statements include the accounts of iCAD, Inc. and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, iCAD France, LLC and iCAD Italy, LLC. All material inter-company transactions and balances have been eliminated in consolidation. The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products for the detection of cancer. The Therapy segment consists of radiation therapy (“Xoft”, “Axxent”) products for the treatment of certain cancers. Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19, COVID-19 In late February 2022, Russian military forces launched significant military action against Ukraine. Sustained conflict and disruption in the region has continued through September 30, 2022 and beyond. Economic, civil, military and political uncertainty may arise or increase in regions where the Company operates or derives revenue. Further, countries from which the Company derives revenue may experience military action and/or civil and political unrest; may be subject to government export controls, economic sanctions, embargoes, or trade restrictions; and experience currency, inflation, and interest rate uncertainties. While the impact to the Company has been limited to date, it is not possible to predict the potential outcome should the conflict expand and/or additional sanctions be imposed. For the fiscal year ended 2021, approximately % of the Company’s total revenue and approximately % of the Company’s export revenue was derived from customers located in Europe. Recently Adopted Accounting Pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, (Subtopic 470-20) 815-40)—Accounting 2020-06”).” 2020-06 Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, 2016-13”), 2016-13 2016-13 2016-13

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 2 – Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurement and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The Company applies the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, which are the following: • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value The assigned level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Money market funds included in cash and cash equivalents in the accompanying consolidated balance sheet are considered a Level 1 measurement as they are valued at quoted market prices in active markets. The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy: Fair Value Measurements as of September 30, 2022 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 17,998 $ — $ — $ 17,998 Total Assets $ 17,998 $ — $ — $ 17,998 Fair Value Measurements as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 $ — $ — $ 30,573 Total Assets $ 30,573 $ — $ — $ 30,573 There were no Level 2 or 3 instruments measured at fair value as of September 30, 2022 or December 31, 2021.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Note 3 - Revenue Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. Disaggregation of Revenue The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments. Three months ended September 30, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,535 $ 671 $ 3,206 Service contracts 1,823 400 2,223 Supply and source usage agreements — 453 453 Disposable applicators — 377 377 Other — 97 97 $ 4,358 $ 1,998 $ 6,356 Timing of Revenue Recognition Goods transferred at a point in time $ 2,510 $ 1,119 $ 3,629 Services transferred over time 1,848 879 2,727 $ 4,358 $ 1,998 $ 6,356 Sales Channels Direct sales force $ 2,947 $ 788 $ 3,735 OEM partners 1,411 — 1,411 Channel partners — 1,210 1,210 $ 4,358 $ 1,998 $ 6,356 Nine months ended September 30, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 9,866 $ 2,376 $ 12,242 Service contracts 5,301 1,155 6,456 Supply and source usage agreements — 1,224 1,224 Disposable applicators — 1,256 1,256 Other — 276 276 $ 15,167 $ 6,287 $ 21,454 Timing of Revenue Recognition Goods transferred at a point in time $ 9,844 $ 3,955 $ 13,799 Services transferred over time 5,323 2,332 7,655 $ 15,167 $ 6,287 $ 21,454 Sales Channels Direct sales force $ 9,347 $ 2,508 $ 11,855 OEM partners 5,820 — 5,820 Channel partners — 3,779 3,779 $ 15,167 $ 6,287 $ 21,454 Three months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 4,454 $ 2,358 $ 6,812 Service contracts 1,554 398 1,952 Supply and source usage agreements — 562 562 Other — 35 35 $ 6,008 $ 3,353 $ 9,361 Timing of Revenue Recognition Goods transferred at a point in time $ 4,454 $ 2,393 $ 6,847 Services transferred over time 1,554 960 2,514 $ 6,008 $ 3,353 $ 9,361 Sales Channels Direct sales force $ 3,629 $ 1,403 $ 5,032 OEM partners 2,379 — 2,379 Channel partners — 1,950 1,950 $ 6,008 $ 3,353 $ 9,361 Nine months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 11,778 $ 6,580 $ 18,358 Service contracts 4,737 1,109 5,846 Supply and source usage agreements — 1,572 1,572 Other — 54 54 $ 16,515 $ 9,315 $ 25,830 Timing of Revenue Recognition Goods transferred at a point in time $ 11,778 $ 6,633 $ 18,411 Services transferred over time 4,737 2,682 7,419 $ 16,515 $ 9,315 $ 25,830 Sales Channels Direct sales force $ 10,691 $ 3,632 $ 14,323 OEM partners 5,824 — 5,824 Channel partners — 5,683 5,683 $ 16,515 $ 9,315 $ 25,830 Products. Service Sources and Source Usage Agreements Disposable applicators Other. Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current non-current Contract balances Balance at Balance at Receivables, which are included in ‘Trade accounts receivable’ $ 8,472 $ 8,891 Current contract assets, which are included in “Prepaid and other assets” $ 1,584 $ 1,895 Non-current $ — $ 844 Contract liabilities, which are included in “Deferred revenue” $ 6,757 $ 6,093 Timing of revenue recognition may differ from timing of invoicing of customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company records net contract assets or contract liabilities on a contract-by-contract non-current non-current Changes in deferred revenue from contracts with customers were as follows: Nine Months Balance at beginning of period $ 6,093 Deferral of revenue 9,195 Recognition of deferred revenue (8,531 ) Balance at end of period $ 6,757 The Company expects to recognize estimated revenues related to performance obligation that are unsatisfied (or partially satisfied) in the amounts of approximately $2.3 million in 2022, $4.2 million in 2023, $0.2 million in 2024 and $0.1 million in 2025.

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Common Share	Note 4 – Net Loss per Common Share The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. A summary of the Company’s calculation of net loss per share is as follows: Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Net loss $ (3,898 ) $ (2,176 ) $ (10,561 ) $ (7,099 ) Shares used in the calculation of basic and diluted net loss per share 25,204 25,053 25,183 24,662 Net loss per share - basic and diluted $ (0.15 ) $ (0.09 ) $ (0.42 ) $ (0.29 ) The shares of the Company’s common stock issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: September 30, 2022 2021 Stock options 2,624,154 2,509,511 Restricted stock — 1,750 Total 2,624,154 2,511,261

Inventories

Inventories	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories	Note 5 – Inventories The Company values its inventory at the lower of cost or net realizable value. Cost includes materials, labor, and manufacturing overhead and is determined using the first-in, first-out September 30, 2022 December 31, 2021 Raw materials $ 2,665 $ 2,962 Work in process 121 173 Finished Goods 3,113 1,279 Inventory Gross 5,899 4,414 Inventory Reserve ( 269 ) (243 ) Inventory Net $ 5,630 $ 4,171

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 6 – Goodwill The Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the reporting unit is less than its carrying value. Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company considered indicators of impairment, and there were no triggering events identified, no indication of impairment of the Company’s goodwill and no impairment charges recorded during the three and nine months ended September 30, 2022 and 2021.

Long-lived assets

Long-lived assets	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Long-lived assets	Note 7 – Long-lived Assets The Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than its carrying value. There is no set interval or frequency for recoverability evaluation. Rather, the determination of when, if at all, an asset (or asset group) is evaluated for recoverability is based on “events and circumstances.” The following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (or asset group) may not be recoverable and thus is to be evaluated for recoverability. • A significant decrease in the market price of a long-lived asset (or asset group); • A significant adverse change in the extent or manner in which a long-lived asset (or asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (or asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (or asset group); and • A current operating period, or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (or asset group). The Company determined there were no such triggering events in the period ended September 30, 2022.

Leases Commitments

Leases Commitments	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Lease Commitments	Note 8 – Lease Commitments Per ASC 842, the Company determines if an arrangement contains a lease at inception. A lease is an operating or financing contract, or part of a contract, that conveys the right to control the use of an identified tangible asset for a period of time in exchange for consideration. At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. In determining the present value of the lease payments, the Company uses its incremental borrowing rate, determined by estimating the Company’s applicable, fully collateralized borrowing rate, with adjustment as appropriate for lease term. The lease term at the lease commencement date is determined based on the non-cancellable Assumptions made by the Company at the commencement date of each lease are re-evaluated In May 2022, the Company entered into an agreement to amend its Irvine operating lease (the “Irvine Amendment”). The Irvine Amendment extended the lease term of the premises by 5 years, or until March 2028. Fixed monthly rent for the space will be incurred at a rate of $2.10 per square foot per year beginning in April 2023, subject to annual increases of $.06 per square foot in 2025 and 2026 as well as annual increases of $0.07 per square foot in 2027 and 2028. The Irvine Amendment includes a five-year option to extend the term. Upon the execution of the Irvine Amendment, which was deemed to be a lease modification, the Company re-evaluated right-of-use right-of-use Right-of-use non-lease non-lease ASC 842 includes a number of reassessment and remeasurement requirements for lessees based on certain triggering events or conditions. There were no impairment indicators identified during the three and nine months ended September 30, 2022 that would require impairment testing of the Company’s right-of-use Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease non-lease Components of Leases: The Company has leases for office space and office equipment. The leases expire at various dates through 2028. Lease Cost Classification Three Months Ended September 30, 2022 Nine Months Ended Operating lease cost - Right of Use Asset Operating expenses $ 214 $ 644 Other information related to leases was as follows: Three Months Nine Months Cash paid from operating cash flows $ 233 $ 698 As of September 30, Weighted-average remaining lease term of operating leases (years) 3.9 Weighted-average discount rate for operating leases 6.3 % Maturity of the Company’s lease liabilities as of September 30, 2022 was as follows: 2022 $ 233 2023 611 2024 642 2025 644 2026 664 2027 685 2028 173 Total lease payments 3,652 Less: imputed interest (664 ) Total lease liabilities 2,988 Less: current portion of lease liabilities (508 ) Long-term lease liabilities $ 2,480

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	Note 9 – Notes Payable (a) Loan and Security Agreement – Western Alliance Bank On March 30, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Western Alliance Bank (the “Bank”) that provided an initial term loan (“Term Loan”) facility of $7.0 million and a $5.0 million revolving line of credit. Obligations to the Bank under the Loan Agreement were secured by a first priority security interest in the Company’s assets, except for certain permitted liens that have priority to the Bank’s security interest by operation of law. On April 27, 2021, the Company repaid its obligations in the aggregate amount of $7,354,283 and terminated the Loan Agreement with the Bank, and the Company’s collateral securing the facility was released. The Company accounted for this repayment and retirement as an extinguishment of the Loan Agreement. The Company recorded a loss on extinguishment of approximately $386,000 at that time related to the repayment and retirement of the Loan Agreement. The loss on extinguishment was composed of approximately $140,000 for a prepayment fee, $122,000 for the unaccrued final payment, $65,000 termination and other fees, and $58,000 for the unamortized discount and other closing costs from origination of the loan. The following amounts are included in interest expense related to the Loan Agreement in the Company’s consolidated statement of operations for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cash interest expense $ — $ — $ — $ 141 Total interest expense $ — $ — $ — $ 141

Stockholders Equity

Stockholders Equity	9 Months Ended
	Sep. 30, 2022
Federal Home Loan Banks [Abstract]
Stockholders Equity	Note 10 – Stockholders Equity (a) Financing Activity On March 2, 2021, the Company entered into an underwriting agreement with Guggenheim Securities, LLC, as representative of the several underwriters thereto, in connection with an underwritten public offering of 1,393,738 shares of the Company’s common stock at an offering price of $18.00 per share. The Offering closed on March 5, 2021 for gross proceeds of approximately $25.1 million and net proceeds of approximately $23.2 million to the Company. (b) Stock-Based Compensation The Company granted options to purchase 0 and 760,000 shares of the Company’s stock during the three and nine months ended September 30, 2022, respectively. The full amount of options were granted in the first nine months of 2022. The Company’s stock-based compensation expense, including options and restricted stock by category is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of revenue $ 1 $ 3 $ 2 $ 20 Engineering and product development 37 73 182 281 Marketing and sales 133 149 441 629 General and administrative 234 431 744 1,172 $ 405 $ 656 $ 1,369 $ 2,102 As of September 30, 2022, there was approximately $2.3 million of total unrecognized compensation cost related to unvested options and restricted stock. That cost is expected to be recognized over a weighted average period of 1.97 years. Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended Nine Months Ended September 30, 2022 2021 2022 2021 Average risk-free interest rate n/a * 0.41% 1.90% 0.28% Expected dividend yield None None None None Expected life n/a * 3.5 years 3.5 years 3.5 years Expected volatility n/a * 65.6%-67.4% 66.3% to 70.5% 65.6% to 67.4% Weighted average exercise price n/a * $15.04 $5.22 $16.61 Weighted average fair value n/a * $6.18 $2.46 $7.34 * The Company granted no options during the three months ended September 30, 2022. The Company’s Treasury zero-coupon The Company did not grant any shares of restricted stock during the three-months ended September 30, 2022 or 2021. The Company granted 0 and 22,488 shares of restricted stock during the nine months ended September 30, 2022 and 2021, respectively. The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from the grant date. All of the Company’s restricted stock grants in 2021 had time-based vesting requirements. The grant date fair value for restricted stock awards is based on the quoted market value of Company stock on the grant date. A summary of stock option activity for all stock option plans for the period ended September 30, 2022 is as follows: Number of Options Weighted Average Exercise Price Intrinsic Value Outstanding as of December 31, 2021 2,486,511 $ 9.27 $ 3,820 Granted 760,000 $ 5.22 $ 3 Exercised (73,500 ) $ 2.45 $ 85,974 Cancelled (548,857 ) $ 11.96 $ — Outstanding as of September 30, 2022 2,642,154 $ 9.44 $ — Options Exercisable as of December 31, 2021 1,619,855 $ 6.47 $ 3,730 Options Exercisable as of September 30, 2022 1,835,848 $ 9.97 $ — The Company issued 44,700 and 73,500 shares of common stock upon the exercise of outstanding stock options in the three and nine months ended September 30, 2022, respectively. The Company received cash proceeds from stock option exercises Employee Stock Purchase Plan In December 2019, the Company’s Board of Directors adopted, and the stockholders approved the 2019 Employee Stock Purchase Plan (“ESPP”), effective January 1, 2020. The ESPP provides for the issuance of up 950,000 shares of common stock, subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. The ESPP may be terminated or amended by the Board of Directors at any time. Certain amendments to the ESPP require stockholder approval. Substantially all of the Company’s employees whose customary employment is for more than 20 hours a week are eligible to participate in the ESPP. Any employee who owns 5% or more of the voting power or value of the Company’s shares of common stock is not eligible to purchase shares under the ESPP. Any eligible employee can enroll in the Plan as of the beginning of a respective quarterly accumulation period. Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year. The Company issued 9,224 and 27,288 shares under the ESPP in the three and nine months ended September 30, 2022 respectively. The Company recorded approximately $11,000 and $30,000 of stock-based compensation expense pursuant to ESPP for the three and nine months ended September 30, 2022, respectively. The next accumulation period under the ESPP commenced on July 1, 2022 and ended on September 30, 2022, and the related shares purchased by the participants were issued in October 2022. As of September 30, 2022, the Company recorded a liability of approximately $32,000 related to employee withholdings in connection with the ESPP accumulation period ended September 30, 2022, which was included as a component of accrued expenses and other current liabilities. In October 2022, the Company suspended the ESPP such that the accumulation period from October 1, 2022 through December 31, 2022 and beyond will not occur.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 11 – Income Taxes The Company had no material unrecognized tax benefits and a deferred tax liability of approximately $5,800 related to tax amortizable goodwill at September 30, 2022. No other adjustments were required under ASC 740, “Income Taxes.” The Company does not expect that its unrecognized tax benefits will materially increase within the next 12 months. The Company did not recognize any interest or penalties related to uncertain tax positions at September 30, 2022. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state tax authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not currently under examination by any federal or state jurisdiction for any tax years.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Reporting	Note 12 – Segment Reporting Operating segments are the components of the Company’s business for which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is the chief executive officer. The Company’s operating segments are generally organized by the type of product or service offered and by geography. Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments: Detection and Therapy. The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of the Company’s radiation therapy products, and related services. The primary factors used by the Company’s CODM to allocate resources are based on revenues, gross profit, operating income or loss, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring The Company does not track its assets by operating segment and the CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Segment revenues: Detection $ 4,359 $ 6,008 $ 15,168 $ 16,515 Therapy 1,997 3,353 6,286 9,315 Total r $ 6,356 $ 9,361 $ 21,454 $ 25,830 Segment gross profit: Detection $ 3,703 $ 5,058 $ 12,918 $ 13,788 Therapy 670 1,654 2,258 4,751 Segment gross profit $ 4,373 $ 6,712 $ 15,176 $ 18,539 Segment operating income (loss): Detection $ (330 ) $ 671 $ 758 $ 1,664 Therapy (948 ) (173 ) (2,954 ) (735 ) Segment operating income (loss): $ (1,278 ) $ 498 $ (2,196 ) $ 929 General, administrative, depreciation and amortization expense $ (2,682 ) $ (2,679 ) $ (8,402 ) $ (7,513 ) Interest expense (7 ) — (7 ) (141 ) Interest income 71 21 89 53 Other expense (2 ) (16 ) (45 ) (41 ) Loss on extinguishment of debt — — — (386 ) Loss before income tax $ (3,898 ) $ (2,176 ) $ (10,561 ) $ (7,099 )

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13 – Commitments and Contingencies Other Commitments The Company is obligated to pay approximately $3.8 million for firm purchase obligations to suppliers for future product and service deliverables and $0.2 million for minimum royalty obligations. Litigation The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on the Company’s operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, “Contingencies.” Legal costs are expensed as incurred.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events In November 2022, the Company eliminated a number of positions, resulting in a charge of approximately million, comprised of severance and related costs. The Company expects the entire amount to be paid in cash before December 31, 2022. The Company has evaluated all other events and transactions subsequent to the balance sheet date to the date of the filing and is not aware of any additional events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the consolidated financial statements.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at September 30, 2022, the results of operations of the Company for the three and nine months ended September 30, 2022 and 2021, cash flows of the Company for the nine months ended September 30, 2022 and 2021, and stockholders’ equity for the Company for the three and nine months ended September 30, 2022 and 2021. Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K
Principles of Consolidation and Business Segments	Principles of Consolidation and Business Segments The condensed consolidated financial statements include the accounts of iCAD, Inc. and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, iCAD France, LLC and iCAD Italy, LLC. All material inter-company transactions and balances have been eliminated in consolidation. The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products for the detection of cancer. The Therapy segment consists of radiation therapy (“Xoft”, “Axxent”) products for the treatment of certain cancers.
Risk and Uncertainty	Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19, COVID-19 In late February 2022, Russian military forces launched significant military action against Ukraine. Sustained conflict and disruption in the region has continued through September 30, 2022 and beyond. Economic, civil, military and political uncertainty may arise or increase in regions where the Company operates or derives revenue. Further, countries from which the Company derives revenue may experience military action and/or civil and political unrest; may be subject to government export controls, economic sanctions, embargoes, or trade restrictions; and experience currency, inflation, and interest rate uncertainties. While the impact to the Company has been limited to date, it is not possible to predict the potential outcome should the conflict expand and/or additional sanctions be imposed. For the fiscal year ended 2021, approximately % of the Company’s total revenue and approximately % of the Company’s export revenue was derived from customers located in Europe.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, (Subtopic 470-20) 815-40)—Accounting 2020-06”).” 2020-06 Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, 2016-13”), 2016-13 2016-13 2016-13

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy: Fair Value Measurements as of September 30, 2022 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 17,998 $ — $ — $ 17,998 Total Assets $ 17,998 $ — $ — $ 17,998 Fair Value Measurements as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 $ — $ — $ 30,573 Total Assets $ 30,573 $ — $ — $ 30,573

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments	The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments. Three months ended September 30, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 2,535 $ 671 $ 3,206 Service contracts 1,823 400 2,223 Supply and source usage agreements — 453 453 Disposable applicators — 377 377 Other — 97 97 $ 4,358 $ 1,998 $ 6,356 Timing of Revenue Recognition Goods transferred at a point in time $ 2,510 $ 1,119 $ 3,629 Services transferred over time 1,848 879 2,727 $ 4,358 $ 1,998 $ 6,356 Sales Channels Direct sales force $ 2,947 $ 788 $ 3,735 OEM partners 1,411 — 1,411 Channel partners — 1,210 1,210 $ 4,358 $ 1,998 $ 6,356 Nine months ended September 30, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 9,866 $ 2,376 $ 12,242 Service contracts 5,301 1,155 6,456 Supply and source usage agreements — 1,224 1,224 Disposable applicators — 1,256 1,256 Other — 276 276 $ 15,167 $ 6,287 $ 21,454 Timing of Revenue Recognition Goods transferred at a point in time $ 9,844 $ 3,955 $ 13,799 Services transferred over time 5,323 2,332 7,655 $ 15,167 $ 6,287 $ 21,454 Sales Channels Direct sales force $ 9,347 $ 2,508 $ 11,855 OEM partners 5,820 — 5,820 Channel partners — 3,779 3,779 $ 15,167 $ 6,287 $ 21,454 Three months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 4,454 $ 2,358 $ 6,812 Service contracts 1,554 398 1,952 Supply and source usage agreements — 562 562 Other — 35 35 $ 6,008 $ 3,353 $ 9,361 Timing of Revenue Recognition Goods transferred at a point in time $ 4,454 $ 2,393 $ 6,847 Services transferred over time 1,554 960 2,514 $ 6,008 $ 3,353 $ 9,361 Sales Channels Direct sales force $ 3,629 $ 1,403 $ 5,032 OEM partners 2,379 — 2,379 Channel partners — 1,950 1,950 $ 6,008 $ 3,353 $ 9,361 Nine months ended September 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 11,778 $ 6,580 $ 18,358 Service contracts 4,737 1,109 5,846 Supply and source usage agreements — 1,572 1,572 Other — 54 54 $ 16,515 $ 9,315 $ 25,830 Timing of Revenue Recognition Goods transferred at a point in time $ 11,778 $ 6,633 $ 18,411 Services transferred over time 4,737 2,682 7,419 $ 16,515 $ 9,315 $ 25,830 Sales Channels Direct sales force $ 10,691 $ 3,632 $ 14,323 OEM partners 5,824 — 5,824 Channel partners — 5,683 5,683 $ 16,515 $ 9,315 $ 25,830
Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers	The following table provides information about receivables, current and non-current Balance at Balance at Receivables, which are included in ‘Trade accounts receivable’ $ 8,472 $ 8,891 Current contract assets, which are included in “Prepaid and other assets” $ 1,584 $ 1,895 Non-current $ — $ 844 Contract liabilities, which are included in “Deferred revenue” $ 6,757 $ 6,093
Summary of Changes in Deferred Revenue	Changes in deferred revenue from contracts with customers were as follows: Nine Months Balance at beginning of period $ 6,093 Deferral of revenue 9,195 Recognition of deferred revenue (8,531 ) Balance at end of period $ 6,757

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows: Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Net loss $ (3,898 ) $ (2,176 ) $ (10,561 ) $ (7,099 ) Shares used in the calculation of basic and diluted net loss per share 25,204 25,053 25,183 24,662 Net loss per share - basic and diluted $ (0.15 ) $ (0.09 ) $ (0.42 ) $ (0.29 )
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The shares of the Company’s common stock issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: September 30, 2022 2021 Stock options 2,624,154 2,509,511 Restricted stock — 1,750 Total 2,624,154 2,511,261

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Current Inventory	September 30, 2022 December 31, 2021 Raw materials $ 2,665 $ 2,962 Work in process 121 173 Finished Goods 3,113 1,279 Inventory Gross 5,899 4,414 Inventory Reserve ( 269 ) (243 ) Inventory Net $ 5,630 $ 4,171

Leases Commitments (Tables)

Leases Commitments (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Components of Lease Expense	The Company has leases for office space and office equipment. The leases expire at various dates through 2028. Lease Cost Classification Three Months Ended September 30, 2022 Nine Months Ended Operating lease cost - Right of Use Asset Operating expenses $ 214 $ 644 Other information related to leases was as follows: Three Months Nine Months Cash paid from operating cash flows $ 233 $ 698 As of September 30, Weighted-average remaining lease term of operating leases (years) 3.9 Weighted-average discount rate for operating leases 6.3 %
Summary of Detained Information of Lease Liabilities	Maturity of the Company’s lease liabilities as of September 30, 2022 was as follows: 2022 $ 233 2023 611 2024 642 2025 644 2026 664 2027 685 2028 173 Total lease payments 3,652 Less: imputed interest (664 ) Total lease liabilities 2,988 Less: current portion of lease liabilities (508 ) Long-term lease liabilities $ 2,480

Notes Payable (Table)

Notes Payable (Table)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Summary of Interest Expense in Consolidated Income Statement	The following amounts are included in interest expense related to the Loan Agreement in the Company’s consolidated statement of operations for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cash interest expense $ — $ — $ — $ 141 Total interest expense $ — $ — $ — $ 141

Stockholders Equity (Tables)

Stockholders Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation Expense Including Options and Restricted Stock by Category	Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of revenue $ 1 $ 3 $ 2 $ 20 Engineering and product development 37 73 182 281 Marketing and sales 133 149 441 629 General and administrative 234 431 744 1,172 $ 405 $ 656 $ 1,369 $ 2,102
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended Nine Months Ended September 30, 2022 2021 2022 2021 Average risk-free interest rate n/a * 0.41% 1.90% 0.28% Expected dividend yield None None None None Expected life n/a * 3.5 years 3.5 years 3.5 years Expected volatility n/a * 65.6%-67.4% 66.3% to 70.5% 65.6% to 67.4% Weighted average exercise price n/a * $15.04 $5.22 $16.61 Weighted average fair value n/a * $6.18 $2.46 $7.34 * The Company granted no options during the three months ended September 30, 2022.
Summary of Stock Option Activity for all Stock Option Plans	A summary of stock option activity for all stock option plans for the period ended September 30, 2022 is as follows: Number of Options Weighted Average Exercise Price Intrinsic Value Outstanding as of December 31, 2021 2,486,511 $ 9.27 $ 3,820 Granted 760,000 $ 5.22 $ 3 Exercised (73,500 ) $ 2.45 $ 85,974 Cancelled (548,857 ) $ 11.96 $ — Outstanding as of September 30, 2022 2,642,154 $ 9.44 $ — Options Exercisable as of December 31, 2021 1,619,855 $ 6.47 $ 3,730 Options Exercisable as of September 30, 2022 1,835,848 $ 9.97 $ —

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	The Company does not track its assets by operating segment and the CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Segment revenues: Detection $ 4,359 $ 6,008 $ 15,168 $ 16,515 Therapy 1,997 3,353 6,286 9,315 Total r $ 6,356 $ 9,361 $ 21,454 $ 25,830 Segment gross profit: Detection $ 3,703 $ 5,058 $ 12,918 $ 13,788 Therapy 670 1,654 2,258 4,751 Segment gross profit $ 4,373 $ 6,712 $ 15,176 $ 18,539 Segment operating income (loss): Detection $ (330 ) $ 671 $ 758 $ 1,664 Therapy (948 ) (173 ) (2,954 ) (735 ) Segment operating income (loss): $ (1,278 ) $ 498 $ (2,196 ) $ 929 General, administrative, depreciation and amortization expense $ (2,682 ) $ (2,679 ) $ (8,402 ) $ (7,513 ) Interest expense (7 ) — (7 ) (141 ) Interest income 71 21 89 53 Other expense (2 ) (16 ) (45 ) (41 ) Loss on extinguishment of debt — — — (386 ) Loss before income tax $ (3,898 ) $ (2,176 ) $ (10,561 ) $ (7,099 )

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - Segment	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Number of Operating Segments	2
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Europe [Member]
Concentration Risk, Percentage		8.60%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Europe [Member] | Revenue Through Exports [Member]
Concentration Risk, Percentage		39%

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets
Total Assets	$ 17,998	$ 30,573
Money Market Accounts [Member]
Assets
Total Assets	17,998	30,573
Level 1 [Member]
Assets
Total Assets	17,998	30,573
Level 1 [Member] | Money Market Accounts [Member]
Assets
Total Assets	$ 17,998	$ 30,573

Revenue - Revenues Disaggregate

Revenue - Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 6,356	$ 9,361	$ 21,454	$ 25,830
Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,206	6,812	12,242	18,358
Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,223	1,952	6,456	5,846
Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	453	562	1,224	1,572
Disposable Applicators [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	377		1,256
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	97	35	276	54
Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,629	6,847	13,799	18,411
Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,727	2,514	7,655	7,419
Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,735	5,032	11,855	14,323
OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,411	2,379	5,820	5,824
Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,210	1,950	3,779	5,683
Detection [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,358	6,008	15,167	16,515
Detection [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,535	4,454	9,866	11,778
Detection [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,823	1,554	5,301	4,737
Detection [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,510	4,454	9,844	11,778
Detection [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,848	1,554	5,323	4,737
Detection [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,947	3,629	9,347	10,691
Detection [Member] | OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,411	2,379	5,820	5,824
Therapy [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,998	3,353	6,287	9,315
Therapy [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	671	2,358	2,376	6,580
Therapy [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	400	398	1,155	1,109
Therapy [Member] | Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	453	562	1,224	1,572
Therapy [Member] | Disposable Applicators [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	377		1,256
Therapy [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	97	35	276	54
Therapy [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,119	2,393	3,955	6,633
Therapy [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	879	960	2,332	2,682
Therapy [Member] | Direct Sales Force [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	788	1,403	2,508	3,632
Therapy [Member] | Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 1,210	$ 1,950	$ 3,779	$ 5,683

Revenue - Summary of Receivable

Revenue - Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Contract with Customer, Asset and Liability [Abstract]
Receivables, which are included in ‘Trade accounts receivable'	$ 8,472	$ 8,891
Current contract assets, which are included in "Prepaid and other assets"	1,584	1,895
Non-current contract assets, which are included in "other assets"	0	844
Contract liabilities, which are included in "Deferred revenue"	$ 6,757	$ 6,093

Revenue - Summary of Changes in

Revenue - Summary of Changes in Deferred Revenue from Contracts with Customers (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Deferred Revenue Disclosure [Abstract]
Balance at beginning of period	$ 6,093
Deferral of revenue	9,195
Recognition of deferred revenue	(8,531)
Balance at end of period	$ 6,757

Revenue - Additional Informatio

Revenue - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Revenue From Contract With Customer [Line Items]
Deferred Revenue To Be Recognized in remainer of fiscal year end	$ 2.3
Unearned amount to recognize in 2023	4.2
Unearned amount to recognize in 2024	0.2
Unearned amount to recognize in 2025	$ 0.1

Net Loss per Common Share - Cal

Net Loss per Common Share - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss	$ (3,898)	$ (2,176)	$ (10,561)	$ (7,099)
Shares used in the calculation of basic and diluted net loss per share	25,204	25,053	25,183	24,662
Earnings Per Share, Basic	$ (0.15)	$ (0.09)	$ (0.42)	$ (0.29)
Earnings Per Share, Diluted	$ (0.15)	$ (0.09)	$ (0.42)	$ (0.29)

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,624,154	2,511,261
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,624,154	2,509,511
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	0	1,750

Inventory - Schedule of Current

Inventory - Schedule of Current Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 2,665	$ 2,962
Work in process	121	173
Finished Goods	3,113	1,279
Inventory Gross	5,899	4,414
Inventory Reserve	(269)	(243)
Inventory	$ 5,630	$ 4,171

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory reserve	$ 269	$ 243

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment loss	$ 0	$ 0

Leases Commitments - Schedule o

Leases Commitments - Schedule of Components of Lease Expense (Detail) - Accounting Standards Update 2016-02 [Member] $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease cost—Right of Use Asset	$ 214	$ 644
Cash paid from operating cash flows for operating leases	$ 233	$ 698
Weighted-average remaining lease term of operating leases (years)	3 years 10 months 24 days	3 years 10 months 24 days
Weighted-average discount rate for operating leases	6.30%	6.30%

Leases Commitments - Summary of

Leases Commitments - Summary of Detained Information of Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
2022	$ 233
2023	611
2024	642
2025	644
2026	664
2027	685
2028	173
Total lease payments	3,652
Less: imputed interest	(664)
Total lease liabilities	2,988
Less: current portion of lease liabilities	(508)
Long-term lease liabilities	$ 2,480	$ 266

Leases Commitments - Additional

Leases Commitments - Additional Information (Detail)	6 Months Ended	9 Months Ended
	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Increase in right of use asset	$ 2,400,000
Irvine Amendment [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating Lease Option To Extend		5 years, or until March 2028
Monthly Rent As per Square Foot		$ 2,100
Irvine Amendment [Member] | Year Two Thousand And Twenty Five [Member]
Lessee, Lease, Description [Line Items]
Rent Per Square Feet		0.06
Irvine Amendment [Member] | Year Two Thousand And Twenty Six [Member]
Lessee, Lease, Description [Line Items]
Rent Per Square Feet		0.06
Irvine Amendment [Member] | Year Two Thousand And Twenty Seven [Member]
Lessee, Lease, Description [Line Items]
Rent Per Square Feet		0.07
Irvine Amendment [Member] | Year Two Thousand And Twenty Eight [Member]
Lessee, Lease, Description [Line Items]
Rent Per Square Feet		0.07

Notes Payable - Summary of Inte

Notes Payable - Summary of Interest Expense in Consolidated Income Statement (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Interest Expense [Line Items]
Total interest expense	$ 7	$ 0	$ 7	$ 141
Western Alliance Bank [Member]
Interest Expense [Line Items]
Cash interest expense	0	0	0	141
Total interest expense	$ 0	$ 0	$ 0	$ 141

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Apr. 27, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Mar. 30, 2020
Debt Instrument [Line Items]
Repayments of Lines of Credit	$ 7,354,283
Gain (Loss) on Extinguishment of Debt		$ 0	$ 0	$ (386)
Western Alliance Bank [Member]
Debt Instrument [Line Items]
Gain (Loss) on Extinguishment of Debt			386,000
Western Alliance Bank [Member] | Debt Prepayment Cost [Member]
Debt Instrument [Line Items]
Debt prepayment cost			140,000
Western Alliance Bank [Member] | Final Payment Of Loan [Member]
Debt Instrument [Line Items]
Final Payment of Loan			122,000
Western Alliance Bank [Member] | Termination Loans [Member]
Debt Instrument [Line Items]
Termination Loans			65,000
Western Alliance Bank [Member] | Unamortized Debt Issuance Expense [Member]
Debt Instrument [Line Items]
Unamortized closing costs			$ 58,000
Term Loan A [Member] | Western Alliance Bank [Member]
Debt Instrument [Line Items]
Credit facility					$ 7,000
Revolving Credit Facility [Member] | Western Alliance Bank [Member]
Debt Instrument [Line Items]
Credit facility					$ 5,000

Stockholders Equity - Options G

Stockholders Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price			$ 5.22
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate		0.41%	1.90%	0.28%
Expected dividend yield	0%	0%	0%	0%
Expected life		3 years 6 months	3 years 6 months	3 years 6 months
Weighted average exercise price		$ 15.04	$ 5.22	$ 16.61
Weighted average fair value		$ 6.18	$ 2.46	$ 7.34
Minimum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		65.60%	66.30%	65.60%
Maximum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		67.40%	70.50%	67.40%

Stockholders Equity - Options_2

Stockholders Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Parenthetical) (Detail) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted	0	760,000

Stockholders Equity - Stock-Bas

Stockholders Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 405	$ 656	$ 1,369	$ 2,102
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	1	3	2	20
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	37	73	182	281
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	133	149	441	629
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 234	$ 431	$ 744	$ 1,172

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 02, 2021	Dec. 31, 2019	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			0	760,000
Common stock, Issued				73,500
Net proceeds from Issue of common stock				$ 0	$ 23,229
Underwritten public offering shares	1,393,738
Offering price, per share	$ 18
Gross proceeds from sale of units	$ 25,100
Net proceeds from sale of units	$ 23,200
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized			$ 2,300	$ 2,300
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 11 months 19 days
2019 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of voting power		5%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			0	0	22,488
Number of shares vested			0	0
Intrinsic value of restricted shares that vested			$ 0	$ 0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, Issued			44,700	73,500
Net proceeds from Issue of common stock			$ 102,000	$ 181,000
2019 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Description of employee stock purchase plan				Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year.
Number of shares issued, Employee Stock Purchase Plans		950,000	9,224	27,288
Stock-based compensation expense			$ 11,000	$ 30,000
Employee-related Liabilities, Current			$ 32,000	$ 32,000
Black Scholes Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			0	760,000

Stockholders Equity - Summary o

Stockholders Equity - Summary of Stock Option Activity for all Stock Option plan (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Beginning balance		2,486,511
Granted	0	760,000
Exercised		(73,500)
Cancelled		(548,857)
Ending Balance	2,642,154	2,642,154
weighted Average, Beginning Balance		$ 9.27
Granted		5.22
Exercised		2.45
Cancelled		11.96
Weighted Average, Ending Balance	$ 9.44	$ 9.44
Intrinsic Value, Beginning Balance		$ 3,820
Granted		3
Exercised		85,974
Intrinsic Value, Ending Balance	$ 0	$ 0
Exercisable, Number of Options	1,835,848	1,835,848	1,619,855
Exerciable, Weighted Average Exercise Price	$ 9.97	$ 9.97	$ 6.47
Exercisable, Intrinsic Value	$ 0	$ 0	$ 3,730

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) $ in Thousands	Sep. 30, 2022 USD ($)
Schedule Of Income Tax Expense [Line Items]
Unrecognized tax benefits	$ 0
Deferred Tax Liabilities, Goodwill	$ 5,800

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment revenues:
Total revenue	$ 6,356	$ 9,361	$ 21,454	$ 25,830
Segment gross profit:
Segment gross profit	4,373	6,712	15,176	18,539
Segment operating income (loss):
Segment operating income (loss)	(1,278)	498	(2,196)	929
General, administrative, depreciation and amortization expense	(2,682)	(2,679)	(8,402)	(7,513)
Interest expense	(7)	0	(7)	(141)
Interest income	71	21	89	53
Other (expense) income	(2)	(16)	(45)	(41)
Loss on extinguishment of debt		0	0	(386)
Loss before provision for income taxes	(3,898)	(2,176)	(10,561)	(7,099)
Product [Member]
Segment revenues:
Total revenue	3,207	6,320	12,242	16,429
Service [Member]
Segment revenues:
Total revenue	3,149	3,041	9,212	9,401
Detection [Member]
Segment gross profit:
Segment gross profit	3,703	5,058	12,918	13,788
Segment operating income (loss):
Segment operating income (loss)	(330)	671	758	1,664
Detection [Member] | Product [Member]
Segment revenues:
Total revenue	4,359	6,008	15,168	16,515
Therapy [Member]
Segment gross profit:
Segment gross profit	670	1,654	2,258	4,751
Segment operating income (loss):
Segment operating income (loss)	(948)	(173)	(2,954)	(735)
Therapy [Member] | Service [Member]
Segment revenues:
Total revenue	$ 1,997	$ 3,353	$ 6,286	$ 9,315

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2022 customer
Schedule Of Geographical Information [Line Items]
Number of reporting segments	2

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	Sep. 30, 2022 USD ($)
Schedule Of Leases [Line Items]
Purchase obligations to suppliers for future product deliverables	$ 3.8
Minimum royalty obligations	$ 0.2

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Millions	Nov. 30, 2022 USD ($)
Subsequent Event [Member]
Severance Costs	$ 0.1